Sustained virologic response for patients with hepatitis C-related cirrhosis: A major milestone, but not quite a cure

Clinical Infectious Diseases

Volumn 57, Issue 2, 2013, Pages 237-239

  Pereira, Oscar Cruz ^a   Feld, Jordan J ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

HCC; hepatocellular carcinoma; screening; sustained virologic response; SVR

Indexed keywords

PEGINTERFERON;

CHILD PUGH SCORE; FOLLOW UP; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; LOW DRUG DOSE; PRIORITY JOURNAL; REVIEW; VIRAL CLEARANCE; FEMALE; HCC; LIVER TUMOR; MALE; NOTE; SCREENING; SUSTAINED VIROLOGIC RESPONSE; SVR; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPATITIS C, CHRONIC; LIVER NEOPLASMS;

HCC; HEPATOCELLULAR CARCINOMA; SCREENING; SUSTAINED VIROLOGIC RESPONSE; SVR;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE;

EID: 84879670660     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit237     Document Type: Review

References (11)

1. Jemal A, Bray F, Ferlay J. Global cancer statistics. CA: Cancer J Clin 2011; 61:69-90.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529-38.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53:1020-2.
4. Yeoman AD, Al-Chalabi T, Karani JB, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 2008; 48:863-70.
5. van der Meer AJ, Heathcote EJ, Janssen HLA Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.
6. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: A cost-utility analysis. Am J Gastroenterol 2003; 98:679-90.
7. Zhang B-H, Yang B-H, Tang Z-Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130:417-22.
8. Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004; 19:1159-72.
9. Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-48.
10. Koh C, Heller T, Haynes-Williams V, et al. Long-term outcome of chronic hepatitis C after sustained virological response to interferon- based therapy. Aliment Pharmacol Ther 2013; 37:887-94.
11. Lok AS, Everhart JE, Wright EC, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011; 140:840-9; quiz e12.